This inventor holds 1 USPTO granted patent. Top assignee: US Government as Represented by the Secretary of the Army. Active years: 2001.
Company Filing History:
Years Active: 2001
Title: The Innovations of William M Vaugn
Introduction
William M Vaugn is an accomplished inventor based in Silver Spring, MD (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled release formulations. His innovative work has led to the creation of a unique patent that addresses the need for sustained release of medications.
Latest Patents
William M Vaugn holds a patent for a sustained release non-steroidal anti-inflammatory and lidocaine PLGA microspheres. This controlled release microcapsule pharmaceutical formulation is designed for burst-free, sustained, programmable release of a non-steroidal anti-inflammatory drug over a duration ranging from 24 hours to 2 months. The formulation comprises a non-steroidal anti-inflammatory drug and a blend of biocompatible, biodegradable poly (lactide/glycolide). This innovation represents a significant advancement in the delivery of medications, enhancing patient care and treatment outcomes.
Career Highlights
William M Vaugn is currently employed by the US Government as represented by the Secretary of the Army. His role involves applying his expertise in pharmaceutical formulations to develop solutions that meet the needs of military personnel and other government entities. His work is characterized by a commitment to innovation and excellence in the field of pharmaceuticals.
Collaborations
Some of William M Vaugn's notable coworkers include John E Van Hamont and Jean A Setterstrom. Their collaborative efforts contribute to the advancement of pharmaceutical technologies and the development of effective treatment options.
Conclusion
William M Vaugn's contributions to the field of pharmaceuticals through his innovative patent and career at the US Government highlight his dedication to improving medication delivery systems. His work continues to impact the healthcare industry positively.